Managing side effects of immune checkpoint inhibitors in breast cancer

被引：22

作者：

Criscitiello, Carmen ^{[1
,2
]}

Corti, Chiara ^{[1
,2
]}

Pravettoni, Gabriella ^{[2
,3
]}

Curigliano, Giuseppe ^{[1
,2
]}

机构：

[1] IRCCS, European Inst Oncol, Div Early Drug Dev Innovat Therapy, Via Ripamonti 435, I-20141 Milan, Italy

[2] Univ Milan, Dept Oncol & Haematol DIPO, Milan, Italy

[3] IRCCS, European Inst Oncol, Appl Res Div Cognit & Psychol Sci, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 162卷

关键词：

Immunotherapy; Adverse events; Management; Immune checkpoint inhibitors; Breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; NIVOLUMAB PLUS IPILIMUMAB; ADVERSE EVENTS; PHASE-III; METASTATIC MELANOMA; DEATH; PROGNOSTIC VALUE; PREDICTIVE-VALUE; DOUBLE-BLIND; OPEN-LABEL;

D O I：

10.1016/j.critrevonc.2021.103354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune-checkpoint inhibitors (ICIs) represent a major development in cancer therapy. The indications for these agents continue to expand across malignancies and disease settings. For years breast cancer (BC) has been considered immunologically quiescent compared with other tumor types. However, recent findings highlighted the immunogenicity of some BCs and paved the way for clinical trials of immunotherapy in BC that led to recent landmark approvals. As a drawback, the safety profile of ICIs is shaped by a specific spectrum of immune-related adverse events (irAEs) that can vary according to ICI class and tumor histology. This review will discuss the epidemiology of these adverse events, their kinetics, risk factors and the most important aspects in their management. A particular focus will be put on BC as the current landscape of immunotherapy for this disease is rapidly increasing the number of people treated with ICIs, thus susceptible to irAEs.

引用

页数：12

共 113 条

[61] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J-J ;

Rutkowski, P. ;

Lao, C. D. ;

Cowey, C. L. ;

Schadendorf, D. ;

Wagstaff, J. ;

Dummer, R. ;

Ferrucci, P. F. ;

Smylie, M. ;

Hogg, D. ;

Hill, A. ;

Marquez-Rodas, I. ;

Haanen, J. ;

Guidoboni, M. ;

Maio, M. ;

Schoffski, P. ;

Carlino, M. S. ;

Lebbe, C. ;

McArthur, G. ;

Ascierto, P. A. ;

Daniels, G. A. ;

Long, G. V. ;

Bastholt, L. ;

Rizzo, J. I. ;

Balogh, A. ;

Moshyk, A. ;

Hodi, F. S. ;

Wolchok, J. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) :1535-1546

[62] Mutational heterogeneity in cancer and the search for new cancer-associated genes [J].

Lawrence, Michael S. ;

Stojanov, Petar ;

Polak, Paz ;

Kryukov, Gregory V. ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Carter, Scott L. ;

Stewart, Chip ;

Mermel, Craig H. ;

Roberts, Steven A. ;

Kiezun, Adam ;

Hammerman, Peter S. ;

McKenna, Aaron ;

Drier, Yotam ;

Zou, Lihua ;

Ramos, Alex H. ;

Pugh, Trevor J. ;

Stransky, Nicolas ;

Helman, Elena ;

Kim, Jaegil ;

Sougnez, Carrie ;

Ambrogio, Lauren ;

Nickerson, Elizabeth ;

Shefler, Erica ;

Cortes, Maria L. ;

Auclair, Daniel ;

Saksena, Gordon ;

Voet, Douglas ;

Noble, Michael ;

DiCara, Daniel ;

Lin, Pei ;

Lichtenstein, Lee ;

Heiman, David I. ;

Fennell, Timothy ;

Imielinski, Marcin ;

Hernandez, Bryan ;

Hodis, Eran ;

Baca, Sylvan ;

Dulak, Austin M. ;

Lohr, Jens ;

Landau, Dan-Avi ;

Wu, Catherine J. ;

Melendez-Zajgla, Jorge ;

Hidalgo-Miranda, Alfredo ;

Koren, Amnon ;

McCarroll, Steven A. ;

Mora, Jaume ;

Lee, Ryan S. ;

Crompton, Brian ;

Onofrio, Robert .

NATURE, 2013, 499 (7457) :214-218

[63] Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial [J].

Lebbe, Celeste ;

Meyer, Nicolas ;

Mortier, Laurent ;

Marquez-Rodas, Ivan ;

Robert, Caroline ;

Rutkowski, Piotr ;

Menzies, Alexander M. ;

Eigentler, Thomas ;

Ascierto, Paolo A. ;

Smylie, Michael ;

Schadendorf, Dirk ;

Ajaz, Mazhar ;

Svane, Inge Marie ;

Gonzalez, Rene ;

Rollin, Linda ;

Lord-Bessen, Jennifer ;

Saci, Abdel ;

Grigoryeva, Elena ;

Pigozzo, Jacopo .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (11) :867-+

[64] Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial [J].

Loi, S. ;

Michiels, S. ;

Salgado, R. ;

Sirtaine, N. ;

Jose, V. ;

Fumagalli, D. ;

Kellokumpu-Lehtinen, P-L ;

Bono, P. ;

Kataja, V. ;

Desmedt, C. ;

Piccart, M. J. ;

Loibl, S. ;

Denkert, C. ;

Smyth, M. J. ;

Joensuu, H. ;

Sotiriou, C. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1544-1550

[65] Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial [J].

Loi, Sherene ;

Giobbie-Hurder, Anita ;

Gombos, Andrea ;

Bachelot, Thomas ;

Hui, Rina ;

Curigliano, Giuseppe ;

Campone, Mario ;

Biganzoli, Laura ;

Bonnefoi, Herve ;

Jerusalem, Guy ;

Bartsch, Rupert ;

Rabaglio-Poretti, Manuela ;

Kammler, Roswitha ;

Maibach, Rudolf ;

Smyth, Mark J. ;

Di Leo, Angelo ;

Colleoni, Marco ;

Viale, Giuseppe ;

Regan, Meredith M. ;

Andre, Fabrice ;

Fumagalli, Debora ;

Gelber, Richard D. ;

Goulioti, Theodora ;

Hiltbrunner, Anita ;

Hui, Rita ;

Roschitzki, Heidi ;

Ruepp, Barbara ;

Boyle, Fran ;

Stahel, Rolf ;

Aebi, Stefan ;

Coates, Alan S. ;

Goldhirsch, Aron ;

Karlsson, Per ;

Kossler, Ingrid ;

Fournarakou, Stamatina ;

Gasca, Adriana ;

Pfister, Rita ;

Ribeli-Hofmann, Sabrina ;

Weber, Magdelena ;

Celotto, Daniela ;

Comune, Carmen ;

Frapolli, Michela ;

Sanchez-Hohl, Magdalena ;

Huang, Hui ;

Mahoney, Caitlin ;

Price, Karen ;

Scott, Karolyn ;

Shaw, Holly ;

Fischer, Susan ;

Greco, Monica .

LANCET ONCOLOGY, 2019, 20 (03) :371-382

[66] Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 [J].

Loi, Sherene ;

Sirtaine, Nicolas ;

Piette, Fanny ;

Salgado, Roberto ;

Viale, Giuseppe ;

Van Eenoo, Francoise ;

Rouas, Ghizlane ;

Francis, Prudence ;

Crown, John P. A. ;

Hitre, Erika ;

de Azambuja, Evandro ;

Quinaux, Emmanuel ;

Di Leo, Angelo ;

Michiels, Stefan ;

Piccart, Martine J. ;

Sotiriou, Christos .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) :860-867

[67] A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study [J].

Loibl, S. ;

Untch, M. ;

Burchardi, N. ;

Huober, J. ;

Sinn, B., V ;

Blohmer, J-U ;

Grischke, E-M ;

Furlanetto, J. ;

Tesch, H. ;

Hanusch, C. ;

Engels, K. ;

Rezai, M. ;

Jackisch, C. ;

Schmitt, W. D. ;

von Minckwitz, G. ;

Thomalla, J. ;

Kuemmel, S. ;

Rautenberg, B. ;

Fasching, P. A. ;

Weber, K. ;

Rhiem, K. ;

Denkert, C. ;

Schneeweiss, A. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1279-1288

[68] The genomic landscape of breast cancer and its interaction with host immunity [J].

Luen, Stephen ;

Virassamy, Balaji ;

Savas, Peter ;

Salgado, Roberto ;

Loi, Sherene .

BREAST, 2016, 29 :241-250

[69] Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance [J].

Martins, Filipe ;

Sofiya, Latifyan ;

Sykiotis, Gerasimos P. ;

Lamine, Faiza ;

Maillard, Michel ;

Fraga, Montserrat ;

Shabafrouz, Keyvan ;

Ribi, Camillo ;

Cairoli, Anne ;

Guex-Crosier, Yan ;

Kuntzer, Thierry ;

Michielin, Olivier ;

Peters, Solange ;

Coukos, Georges ;

Spertini, Francois ;

Thompson, John A. ;

Obeid, Michel .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (09) :563-580

[70] Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab [J].

Menzies, A. M. ;

Johnson, D. B. ;

Ramanujam, S. ;

Atkinson, V. G. ;

Wong, A. N. M. ;

Park, J. J. ;

McQuade, J. L. ;

Shoushtari, A. N. ;

Tsai, K. K. ;

Eroglu, Z. ;

Klein, O. ;

Hassel, J. C. ;

Sosman, J. A. ;

Guminski, A. ;

Sullivan, R. J. ;

Ribas, A. ;

Carlino, M. S. ;

Davies, M. A. ;

Sandhu, S. K. ;

Long, G. V. .

ANNALS OF ONCOLOGY, 2017, 28 (02) :368-376

← 2 3 4 5 6 7 8 9 10 11 →